Histone deacetylase inhibitors (HDI) 
Introduction
The accumulation of genetic abnormalities is a major hallmark of cancer, but recent work has indicated that epigenetic change is also an important molecular determinant and may be a critical step in carcinogenesis (1) (2) (3) . During cancer development, genes are transcriptionally silenced not only by mutations but also by DNA hypermethylation and histone modifications, which are important early events (1) (2) (3) (4) (5) (6) .
Of the epigenetic modifications, histone acetylation/deacetylation is a well-studied paradigm. Histone acetyltransferases and histone deacetylases (HDAC) determine the histone acetylation status and thus regulate gene expression, growth, development, and differentiation in both normal and cancer cells (7) (8) (9) . HDACs form dynamic complexes containing diverse required and optional proteins, allowing great functional flexibility for silencing and chromatin remodeling (10) (11) (12) (13) (14) . HDACs interact with DNA methyltransferases (DNMT) and methyl CpG-binding domain (MBD) proteins, which are associated with CpG island methylation, another epigenetic modification involved in transcriptional repression and heterochromatin (15) (16) (17) (18) .
Five mammalian members of the MBD family have been identified: MeCP2 and MBD1-MBD4 (19) . All MBD family members recruit various HDAC-containing repressor complexes, which lead to silencing by generating repressive chromatin structures at and near the relevant binding sites (20) (21) (22) (23) (24) (25) (26) . MBD protein binding is determined by DNA methylation status and sequence context. MBD1, MBD2, MBD4, and MeCP2 bind methylated DNA, whereas MBD3 is unable to selectively recognize and bind methylated DNA (26) (27) (28) . Thus, MBD binding is determined by its ability to distinguish methylation status and recognize sequence context.
Frequent co-occurrence of aberrant DNA methylation and histone deacetylation in cancers suggests that these processes are functionally linked in carcinogenesis (29) (30) (31) . As these epigenetic changes can be reversed by DNA or histone modification, HDACspecific small-molecule inhibitors (HDI) have shown anticancer activity (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) and have been found to differentially affect growth, differentiation, and death of cancer and normal cells with little toxicity to normal cells (34) (35) (36) (37) (38) (39) (40) (41) . However, the mechanism(s) by which HDACs selectively inhibit cancer cell growth and/or promote cancer cell death is not yet well understood.
Here, we investigated the mechanisms of HDI-induced growth inhibition and death in lung cancer cells. We identified MBD3 as playing an important role in mediating the HDI-induced gene regulations associated with cancer-selective cell death. In lung cancer and normal cells, the distribution of MBD3 in the cell and genome was distinctly regulated by HDIs and was associated with HDI target genes. Silencing of MBD3 abolished the ability of HDIs to induce cancer-specific gene expression and death, whereas altered expressions of the HDI-regulated p21 WAF1/Cip1 and ErbB2 genes induce cancer-specific growth inhibition. Taken together, these findings indicate that MBD3 imparts HDI-induced selectivity in cancer cells via differential transcriptional regulation.
Reverse transcription-PCR analysis. Reverse transcription-PCR (RT-PCR) was done as described (42) (43) (44) using primers as follows: glyceraldehyde-3-phosphate dehydrogenase (GAPDH )-forward (5V -GTCAACGGAA-TTTGGTCTGTATT-3V ) and GAPDH-reverse (5V -AGTCTTCTGGGTGGCA-GTGAT-3V ), p21 WAF1/Cip1 -forward (5V -CCTCCTCGGCCCAGTGGAC-3V ) and p21 WAF1/Cip1 -reverse (5V -CCGTTTTCGACCCTGAGAG-3V ), E2F1-forward (5V -CTTGGCCGGGGCCCCTGCGG-3V ) and E2F1-reverse (5V -TGTGGGCCGGGG-CGCCTGGG-3V ), cyclin D1-forward (5V -CCTCTTGTGCCACAGATG-3V ) and cyclin D1-reverse (5V -GATGTCCACGTCCCGCAC-3V ), cyclin B1-forward (5V -CCTGAGCCAGAACCTGAGCC-3V ) and cyclin B1-reverse (5V -AGTCAC-CAATTTCTGGAGGG-3V ), 14-3-3r-forward (5V -GTGACGACAAGAAGCG-CATCA-3V ) and 14-3-3r-reverse (5V -GTCGGCCGTCCACAGTGTCAG-3V ), ErbB2 -forward (5V -TGGCTGCAAGAAGATCTTTG-3V ) and ErbB2-reverse (5V -TGCAGTTGACACACTGGGTG-3V ), E-cadherin-forward (5V -CTCAAGCT-CGCGGATAACCAG-3V ) and E-cadherin -reverse (5V -AGGCCCCTGTG-CAGCTGGCTC-3V ), TS-forward (5V -CCTCTGATGGCGCTGCCTCC-3V ) and TS-reverse (5V -GGATGCGGATTGTACCCTTC-3V ), H2AX-forward (5V -ATGT-CGGGCCGCGGCAAG-3V ) and H2AX-reverse (5V -GTACTCCTGGGAGG-CCTG-3V ), and MBD3-forward (5V -AAGCCCGACCTGAACACGGCG-3V ) and MBD3-reverse (5V -CTAGACGTGCTCCATCTCCGG-3V ).
Plasmid constructs. To generate mammalian expression vectors for p21 WAF1/Cip1 and ErbB2, full-length cDNAs were produced by RT-PCR from RNA of 293T cells using primers as follows: p21 WAF1/Cip1 (5V -CCGGAATT-CATGTCAGAACCGGCTGGG-3V and 5V -CCGCTCGAGGGGCTTCCTCTTG-GAGAAG-3V ) and ErbB2 (5V -CTCAAGCTTCCATGGAGCTGGCGGCCTTG-3V and 5V -GCCCTCGAGTCACACTGGCACGTCCAGAC-3V ). The fragments of p21 WAF1/Cip1 and ErbB2 were inserted into Flag-tagged pcDNA3.1 (Invitrogen, Carlsbad, CA) at the EcoRI and XhoI sites and pcDNA3 (Invitrogen) at the HindIII and Xho I sites, respectively. Double-stranded small interfering RNAs (siRNA) for ErbB2 and MBD3 were generated using pSUPER vector (42) . The siRNA primers designed for targets, AAATTC-CAGTGGCCATCAA and AGACGGCGTCCATCTTCAA, according to ErbB2 and MBD3 mRNA sequences, respectively, are as follows: ErbB2 (5V -GATCCCCAAATTCCAGTGGCCATCAATTCAAGAGATTGATGGCCACTGGA-ATTTTTTTTGGAAA-3Vand 5V -AGCTTTTCCAAAAAAAATTCCAGTGGCCAT-CAATCTCTTGAATTGATGGCCACTGGAATTTGGG-3V ) and MBD3 (5V -GATCCCCAGACGGCGTCCATCTTCAATTCAAGAGATTGAAGATG-GACGCCGTCTTTTTGGAAA-3Vand 5V -AGCTTTTCCAAAAAAGACGGCGTC-CATCTTCAATCTCTTGAATTGAAGATGGACGCCGTCTGGG-3V ).
Immunoblotting and immunofluorescence staining. Immunoblotting and immunostaining were done as described previously (42) . Flagp21 WAF1/Cip1 , ErbB2, and MBD3 were detected with anti-Flag (Sigma), anti-ErbB2 (NeoMarkers, Fremont, CA) and anti-MBD3 (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies, respectively.
Chromatin immunoprecipitation assay. The chromatin immunoprecipitation assay with antibodies against acetylated histones 3 and 4 (Upstate Biotechnology, Lake Placid, NY), HDAC1 and HDAC2 (Zymed, San Francisco, CA), DNMT1, and MBD1-MBD3 (Santa Cruz Biotechnology) was done as described previously (44) . The immunoprecipitate was amplified using promoter-specific primers as follows: p21 WAF1/Cip1 (5V -CCTTGCCTGCCAGAGGGG-3Vand 5V -CAGCTGCTCACACCTCAG-3V ), ErbB2 (5V -CCCGGACTCCGGGGGAGG-3V and 5V -CCCGGGGGGCTCCCCTGG-3V ), and E-cadherin (5V -GCAGTGAGCTGTGATCGCACC-3Vand 5V -GAGAGGGG-GTGCGTGGCTGC-3V ).
Results
Trichostatin A affects gene expression differently in lung cancer and normal cells. Based on the previous reports that HDIs exhibited cancer-selective cytotoxicity (34-41), we first tested cytotoxicity of HDIs, including trichostatin A, scriptaid, and sodium butyrate, on NHBE cells, bronchial epithelial cells immortalized by SV40 (BEAS-2B), and several cancer cells, alveolar epithelial adenocarcinoma A549, epithelial-like sub-bronchial gland adenocarcinoma CALU-3, pleural effusion adenocarcinoma H460, adenocarcinoma H23, bronchioalveolar carcinoma H358, and nonsmall cell lung cancer H157 and H226. HDIs inhibited cell growth highly by f80% to 90% in all the tested lung cancer cells but only by f20% in NHBE cells and f40% in nontransformed BEAS-2B cells (data not shown), suggesting that HDIs inhibit cell growth more effectively in cancerous lung cells than in normal lung cells. We next examined another normal human lung fibroblast WI38 and its derivative SV40-transformed VA13 cells. HDIs inhibited the growth of VA13 cells (f90%) but had little effect on WI38 cell growth (f20%; data not shown), indicating that HDIs efficiently induce growth inhibition and cell death of transformed (VA13) but not normal (WI38) lung cells. Collectively, these results support the notion that HDIs inhibit cell growth more effectively in lung cancer cells than in primary normal (NHBE and WI38) and nontransformed (BEAS-2B) lung cells, consistent with the previous reports (34) (35) (36) (37) (38) (39) (40) (41) .
The differential growth inhibition and death of cancer and normal cells treated with HDIs prompted us to examine possible mechanisms underlying this effect. HDAC activity plays an important role in regulating gene expression. Thus, we examined the possibility that HDIs could differentially modulate transcriptional profiles of genes in lung cancer and normal cells leading to the observed cancer-specific cytotoxicity. To identify potential genes mediating HDI-induced differential cytotoxicity in lung cancer and normal cells, we analyzed the expression profiles of trichostatin A-regulated genes in lung cancer (A549) and normal (NHBE) cells by performing microarray in cells treated with or without trichostatin A. We first identified trichostatin A-responsive genes that were up-regulated or down-regulated in A549 cells but were not altered or differentially regulated in NHBE cells (data not shown) and selected differentially expressed genes as being possibly associated with the cancer-selective mechanism of trichostatin A-induced growth inhibition and chromatin remodeling (Table 1) and then confirmed our microarray data by RT-PCR (Fig. 1A) . Consistent with our microarray data (Table 1) , trichostatin A efficiently induced the expression of the gene encoding p21 WAF1/Cip1 , a cyclin-dependent kinase inhibitor leading to G 1 cell cycle arrest, in A549 and H460 cancer cells but not in NHBE cells (Fig. 1A) . In contrast, RT-PCR confirmed our microarray data by showing that the ErbB2 gene, a clinically significant kinase implicated in cell growth (45) , was down-regulated by trichostatin A in cancer cells but not in NHBE cells (Fig. 1A) . Interestingly, expression of the E-cadherin gene was decreased by trichostatin A in A549 cells but not in either H460 or NHBE cells (Fig. 1A) .
We next examined differential expression of p21 WAF1/Cip1 and ErbB2 genes in additional lung cancer and normal cells. Our RT-PCR results revealed that although the expression of genes encoding p21 WAF1/Cip1 and ErbB2 was not altered in normal lung WI38 cells the expression of p21 WAF1/Cip1 gene was increased and the expression of ErbB2 gene was reduced by trichostatin A in its transformed VA13 cells (Fig. 1B) . Trichostatin A also induced the expression of p21 WAF1/Cip1 gene and reduced the expression of ErbB2 gene in other CALU-3, H23, H358, and H157 lung cancer cells (Fig. 1B) . Interestingly, the expression of p21 WAF1/Cip1 gene was not affected, but the expression of ErbB2 was reduced by trichostatin A in BEAS-2B cells (Fig. 1B) , indicating that trichostatin A-induced transcriptional regulation profiles in BEAS-2B cells differ between normal (expression of p21 WAF1/Cip1 gene) and cancer (expression of ErbB2 gene) cells. Together, these results suggest that trichostatin A differentially modulates gene expression in lung cancer and normal cells and may target distinct genes for transcriptional regulation. Up-regulation of p21 WAF1/Cip1 and down-regulation of ErbB2 play roles in trichostatin A-induced cancer cell growth inhibition. To study whether differential trichostatin A-induced gene regulation was functionally linked to cancer-selective cell death, we evaluated the roles of p21 WAF1/Cip1 up-regulation and ErbB2 down-regulation in growth inhibition of A549 cells. We first tested whether transcriptional modulation was required for HDIinduced cancer selective death. Cotreatment with trichostatin A and the transcription blocker, actinomycin D, significantly alleviated the death of cancer cells in comparison with cultures treated with trichostatin A alone or actinomycin D alone (data not shown). This indicates that transcription is required for HDIinduced cancer cell death.
We next examined cancer cell growth inhibition following upregulation of p21 WAF1/Cip1 and down-regulation of ErbB2 ( Fig. 2A) , which occurred in the trichostatin A-treated cancer cells (Table 1 ; Fig. 1 ). Overexpression of exogenous p21 WAF1/Cip1 inhibited growth of A549 cells by f60% (Fig. 2B, top) , indicating that induction of p21 WAF1/Cip1 expression can inhibit cancer cell growth in the absence of trichostatin A treatment. The growth inhibition of A549 cells 3 days after p21 WAF1/Cip1 overexpression (Fig. 2B, top) was similar to that seen in A549 cells treated with 0.5 Amol/L trichostatin A for 2 days (compare with Fig. 2B, bottom) . We then evaluated the effect of ErbB2 down-regulation on A549 cell growth inhibition (Fig. 2B) . Knockdown of ErbB2 expression by siRNA enhanced the growth inhibition of A549 cells within 3 days in the absence of trichostatin A (Fig. 2B, top) , consistent with the results of p21 WAF1/Cip1 upregulation. Taken together, these results indicate that up-regulation of p21 WAF1/Cip1 or down-regulation of ErbB2 can inhibit the growth of A549 cells, providing support for our hypothesis that these trichostatin A-induced gene up-regulation/down-regulations may mediate the cancer-selective growth inhibition.
As either p21 WAF1/Cip1 up-regulation (f55%) or ErbB2 downregulation (f52%) inhibited cell growth to levels lower than those induced by 0.2 Amol/L (f68%; Fig. 2B , top and middle) or 0.5 Amol/L trichostatin A (f80%; Fig. 2B , top and bottom), we next tested these effects in combination. The growth inhibition effect of p21 WAF1/Cip1 up-regulation (f84%) or ErbB2 down-regulation (f83%) in the presence of 0.2 or 0.5 Amol/L trichostatin A was slightly higher than that of 0.2 Amol/L trichostatin A alone (f68%) and similar to that of 0.5 Amol/L trichostatin A alone (f80%; Fig. 2B ), indicating that the combinatory effect of the gene upregulation/down-regulation with trichostatin A seems to be relatively small compared with those induced by trichostatin A alone. These observations suggest that p21 WAF1/Cip1 up-regulation and ErbB2 down-regulation induced by trichostatin A may be sufficient and potent for growth inhibition of A549 cells; consequently, either exogenous expression of p21 WAF1/Cip1 or silencing of ErbB2 may not enhance the growth inhibition. In addition, A549 cells expressing both the p21 WAF1/Cip1 expression vector and the ErbB2-targeting siRNA showed growth inhibitions similar to those following expression of either alone without regard to trichostatin A treatment (Fig. 2B) . These results indicate that either up-regulation of p21 WAF1/Cip1 expression or down-regulation of ErbB2 alone may play a role in growth inhibition of A549 cells.
To further support the importance of p21 WAF1/Cip1 up-regulation and/or ErbB2 down-regulation in trichostatin A-induced cancerselective growth inhibition, cell growth was measured in p21 WAF1/Cip1 -knockout (HCT116-p21 WAF1/Cip1 -KO) and p21
stably expressing HCT116 cells (HCT116-p21 WAF1/Cip1 -WT) with or without silencing of the ErbB2 gene (si-ErbB2; Fig. 2C ). Silencing of ErbB2 induced growth inhibition of HCT116-p21 WAF1/Cip1 -WT cells (33%) by >2-fold that of HCT116-p21 WAF1/Cip1 -KO cells (12%) without trichostatin A. In addition, trichostatin A efficiently induced growth inhibition of HCT116-p21 WAF1/Cip1 -WT cells by >2-fold that observed in HCT116-p21 WAF1/Cip1 -KO cells (75% versus 33%, respectively; Fig. 2C ), indicating that p21 WAF1/Cip1 is required for efficient trichostatin A-induced inhibition of cancer cell growth. We next examined whether constitutive expression of ErbB2 could block trichostatin A-mediated growth inhibition. Following overexpression of exogenously introduced ErbB2, the growth inhibition effect of trichostatin A was alleviated in both HCT116-p21 WAF1/Cip1 -WT (68-35%) and HCT116-p21 WAF1/Cip1 -KO cells (30-13%; Fig. 2D ), indicating that cells overexpressing ErbB2 do not exhibit efficient trichostatin A-induced growth inhibition. Taken together, these findings suggest that trichostatin A-induced up-regulation of p21 WAF1/Cip1 and down-regulation of ErbB2 may be important determinants for HDI-induced lung cancer cell cytotoxicity.
Release of MBD3 from the p21
WAF1/Cip1 promoter and its recruitment to the ErbB2 promoter in trichostatin Atreatedlung cancer cells. To investigate the molecular mechanism underlying HDI-mediated differential transcription in lung cancer and normal cells, we examined the promoters of the differentially expressed p21 WAF1/Cip1 (Fig. 3A) , ErbB2 (Fig. 3B) , and E-cadherin (Fig. 3C) genes. Because HDIs mainly act on repression/derepression rather than activation/inactivation of transcriptional regulation, we used a chromatin immunoprecipitation assay to study the recruitment of components in the HDAC complex, which is generally associated with repression/derepression processes. Trichostatin A treatment increased the acetylation status of histone 3 (data not shown) and histone 4 (Fig. 3A, Ac-H4 ) on the p21 WAF1/Cip1 promoter in both normal and cancer cells, suggesting that the induction of histone acetylation by trichostatin A may result in opening of nearby chromatin in both normal and cancerous lung cells. In contrast, the association of HDAC2 with the p21 WAF1/Cip1 promoter increased following trichostatin A treatment in NHBE Figure 3 . Recruitment of MBD1-MBD3 proteins. A to C, chromatin immunoprecipitation assays at the p21 WAF1/Cip1 (A), ErbB2 (B ), and E-cadherin (C ) promoters in NHBE, A549, H460, H358, WI38, VA13, CALU-3, or H23 cells. D, association of MBD3 with the p21 WAF1/Cip1 and ErbB2 promoters in trichostatin A-treated immortalized BEAS-2B and cancer (H226 and H157) cells. Chromatin immunoprecipitation assays were done following treatment without (none ) or with 0.5 Amol/L trichostatin A for 24 hours. Anti-acetylated histone H4 (Ac-H4), anti-HDAC2, anti-DNMT1, and anti-MBD antibodies were used to pull-down acetylated histone, HDAC2, DNMT1, and MBD (MBD1-MBD3) proteins, respectively. The negative control was immunoprecipitation without antibody (no Ab ) and the positive control consisted of 0.1% of the total chromatin sample before immunoprecipitation (Before IP ). Pull-down chromatin pools were PCR amplified with specific primers for the p21 WAF1/Cip1 (p21 promoter; A and D ), ErbB2 (ErbB2 promoter; B and D ), and E-cadherin (E-cadherin promoter; C ) promoters. The primer sets were designed to amplify regions containing conserved GC boxes in each promoter are listed in Materials and Methods.
Role of MBD3 in Cancer-Selective Cytotoxicity by HDIs www.aacrjournals.org and WI38 cells but decreased in cancer cells (Fig. 3A) . In the presence of trichostatin A, the association of DNMT1 with the p21 WAF1/Cip1 promoter increased in normal cells, whereas its association was absent or differed in cancer cell lines. Additionally, chromatin immunoprecipitation analyses with anti-MBD1-MBD3 antibodies revealed that these transcriptional repressor proteins were differentially associated with the p21 WAF1/Cip1 promoter in cancer and normal lung cells before and after trichostatin A treatment (Fig. 3A) . Following trichostatin A treatment, the association of MBD1 and MBD3 with the p21 WAF1/Cip1 promoter decreased in cancer cells and increased in NHBE and WI38 cells (Fig. 3A) , indicating that the composition of the transcriptional repressor complex located on the p21 WAF1/Cip1 promoter differed in normal and cancer cells. The recruitment of MBD2 to the p21 WAF1/Cip1 promoter was observed in normal NHBE and WI38 cells and was not affected by trichostatin A. In addition, the recruitment of MBD2 to the p21 WAF1/Cip1 promoter was absent in A549, H460, and H358 cancer cells or was decreased by trichostatin A in CALU-3 and H23 cells (Fig. 3A) . These results seem to suggest that trichostatin A-induced up-regulation of p21 WAF1/Cip1 in lung cancer cells may be associated with the cancer-specific dissociations of MBD1 and MBD3 at the p21 WAF1/Cip1 promoter. Similar analyses of the ErbB2 promoter revealed that trichostatin A had little effect on histone acetylation in normal NHBE and WI38 cells but induced histone acetylation of this promoter in cancer cell lines, except for CALU-3 and H23 cells (Fig. 3B) . Analysis of histone acetylation and transcriptional regulator association/dissociation at the ErbB2 promoter revealed no apparent difference in NHBE and WI38 cells with and without trichostatin A treatment (Fig. 3B) , whereas the cancer cell lines showed significantly enhanced recruitment of MBD3 following trichostatin A treatment. We observed slight or negligible changes in the associations of HDAC2, MBD1, and MBD2 with the ErbB2 promoter in trichostatin Atreated cancer cells (Fig. 3B) and noted a significant release of DNMT1 from the ErbB2 promoter following trichostatin A treatment in cancer cells (Fig. 3B) . Collectively, these results suggest that trichostatin A-induced down-regulation of ErbB2 in lung cancer cells may be implicated with the cancer-specific recruitment of MBD3 at the ErbB2 promoter.
In contrast to the cancer-selective regulation of p21
and ErbB2 following trichostatin A treatment, transcription of the E-cadherin gene decreased slightly in A549 cells, increased in H460 cells, and remained unchanged in NHBE cells (Fig. 1A) . Our analyses revealed slight increases in histone acetylation and increased association of MBD1-MBD3 and DNMT1 with the E-cadherin promoter in trichostatin A-treated NHBE cells (Fig. 3C) . However, HDAC2 was not associated with the E-cadherin promoter of NHBE cells (Fig. 3C) , perhaps accounting for the minimal change in E-cadherin transcription in these cells under conditions that would seem to favor transcription. In trichostatin A-treated A549 cells, we observed recruitment of MBD1, MBD2, DNMT1, and HDAC2 to the E-cadherin promoter but no recruitment of MBD3 (Fig. 3C) , perhaps accounting for the slight repression of E-cadherin expression observed in these cells. In trichostatin A-treated H460 cells, we observed decreased association of HDAC2 and MBD3, increased association of MBD2, and no change in recruitment of MBD1 (Fig. 3C ). These differences in E-cadherin promoter recruitment and histone acetylation patterns between A549 and H460 cells likely account for the noted differences in the transcriptional expression of E-cadherin in these two cancer cell types (Fig. 1A) . Taken together, the chromatin immunoprecipitation data from the E-cadherin promoter suggest that (a) increased association of MBD1 and MBD2 with the promoter has no effect on transcription, but recruitment of HDAC2 along with MBD1 and MBD2 can induce transcriptional repression, and (b) release of HDAC2 and MBD3 from the promoter can induce transcriptional up-regulation. To further explore whether release/recruitment of MBD3 was correlated with transcriptional up-regulation/down-regulation by trichostatin A in cancer cells, we evaluated the association of MBD1-MBD3 with p21 WAF1/Cip1 and ErbB2 promoters in other lung cancer cell lines (H226 and H157). The association of MBD1 and MBD2 at both p21 WAF1/Cip1 and ErbB2 promoters was not altered by trichostatin A in H226 and H157 cells (Fig. 3D) . Together with the chromatin immunoprecipitation results from other cancer cell lines (Fig. 3A and B) , these observations suggest the association of MBD1 and MBD2 at p21 WAF1/Cip1 and ErbB2 promoters differed in cancer cell lines. In contrast, MBD3 was released from the p21 WAF1/Cip1 promoter and it was recruited to the ErbB2 promoter by trichostatin A in these lung cancer cells. Together, the release/ recruitment of MBD3 at two trichostatin A-responsive promoters (Fig. 3A , B, and D) was in good agreement with up-regulation/ down-regulation of these genes ( Fig. 1A and B) .
Additionally, the association of MBD1 with the p21 WAF1/Cip1 and ErbB2 promoters was slightly increased, but the association of MBD2 was not altered at both promoters by trichostatin A in the immortalized BEAS-2B cells (Fig. 3D) . The association of MBD3 increased at both p21 WAF1/Cip1 and ErbB2 promoters by trichostatin A in BEAS-2B cells (Fig. 3D) , suggesting that the association of MBD3 with these promoters differs between normal (recruitment of MBD3 to the p21 WAF1/Cip1 promoter) and cancer (the recruitment of MBD3 to the ErbB2 promoter) lung cells (Fig. 3A and B) . These results further support the possibility that the trichostatin A-induced transcriptional modulation of p21 WAF1/Cip1 and ErbB2 genes ( Fig. 1B ; no change in p21 WAF1/Cip1 expression and downregulation of ErbB2 expression by trichostatin A in BEAS-2B cells) may be related with the association of MBD3 at these promoters ( Fig. 3D ; the recruitment of MBD3 to p21 WAF1/Cip1 and ErbB2 promoters by trichostatin A). As the results of our p21 WAF1/Cip1 , ErbB2, and E-cadherin promoter analyses in lung normal, immortalized, and cancer cells indicate that release and recruitment of MBD3 are associated with transcriptional up-regulation and down-regulation, respectively, we propose that release and recruitment of MBD3 at the promoters is implicated in transcriptional derepression and repression.
MBD3 mediates trichostatin A-induced cancer-selective gene expression and cytotoxicity. Because MBD3 dissociates from the cancer-selective, up-regulated p21 WAF1/Cip1 promoter and associates with the cancer-selective down-regulated ErbB2 promoter in response to trichostatin A (Fig. 3) , we evaluated the effect of MBD3 silencing on trichostatin A-induced gene regulation and lung cancer cell death. Silencing of MBD3 by siRNA abrogated the trichostatin A-induced ErbB2 down-regulation, although it did not affect the p21 WAF1/Cip1 up-regulation by trichostatin A (Fig. 4A) . Additionally, the knockdown of MBD3 blocked growth inhibition in response to trichostatin A (Fig. 4B) , suggesting that MBD3 is required for HDI-induced cytotoxicity of lung cancer cells. In A549 cells expressing the MBD3-specific siRNA, treatment with 0.5 Amol/L trichostatin A for 3 days induced only 45% growth inhibition compared with f80% growth inhibition in cells not expressing the MBD3-siRNA (Fig. 4B, top) . In H460 cells expressing the MBD3-siRNA, trichostatin A induced only 30% growth inhibition versus 80% in nonsilenced cells (Fig. 4B, bottom) . Collectively, these results indicate that MBD3 is required for efficient trichostatin A-induced gene regulation and cell death in lung cancer cells.
To determine whether MBD3 silencing in normal lung cells may affect the HDI-induced responses, we next assessed the expression of p21 WAF1/Cip1 and ErbB2 genes and growth inhibition with or without trichostatin A following silencing MBD3 in normal (WI38) Role of MBD3 in Cancer-Selective Cytotoxicity by HDIs www.aacrjournals.org and its transformed derivative (VA13) lung cells. The expression of p21 WAF1/Cip1 and ErbB2 genes was not affected by the MBD3 knockdown in WI38 cells without regard to trichostatin A treatment (Fig. 4C, left) . In VA13 cells expressing MBD3-siRNA, the ErbB2 down-regulation by trichostatin A (Fig. 1B) was not observed, whereas the p21 WAF1/Cip1 expression (Fig. 1B) was not affected (Fig. 4C, right) , consistent with the results from other cancer cells (Fig. 4A) . These results suggest that silencing of MBD3 by siRNA abrogate the trichostatin A-induced ErbB2 downregulation in cancer cells but may not affect its expression in normal cells, further supporting the cancer-specific role of MBD3 in trichostatin A-mediated differential transcriptional regulation in normal and cancer cells. Additionally, silencing of MBD3 had little effect on the growth of trichostatin A-unresponsive normal WI38 cells before and after trichostatin A treatment (Fig. 4D, top) , whereas silencing of MBD3 in trichostatin A-responsive VA13 cells inhibited the trichostatin A-induced cytotoxicity by about half ( from 48% to 18% by 0.2 Amol/L trichostatin A and from 82% to 38% by 0.5 Amol/L trichostatin A, following expressing the MBD3-siRNA; Fig. 4D, bottom) , supporting that MBD3 is necessary for cancer-selective cytotoxicity induced by trichostatin A in lung cancer cells.
Finally, we used an immunofluorescence staining to examine the cellular localization of MBD3 in normal and cancer cells with and without trichostatin A treatment. In NHBE cells before trichostatin A treatment, MBD3 was located primarily in the cytoplasm, with some MBD3 proteins localizing to the nucleus (Fig. 5I) . Following trichostatin A treatment, the majority of the MBD3 proteins were localized in the nucleus (Fig. 5J) , suggesting that trichostatin A can induce nuclear localization of MBD3 in NHBE cells. In contrast, the majority of MBD3 proteins were located in the nucleus of BEAS-2B (Fig. 5K ) and A549 and H460 cells (Fig. 5M and O ) before trichostatin A treatment and then formed micronuclei and/or dispersed throughout the cells in response to trichostatin A in A549 and H460 cells ( Fig. 5N and P) but not NHBE and BEAS-2B cells (Fig. 5J and L) . These observations suggest that the cellular location of MBD3 differs between normal and cancer lung cells and may form the basis for their differential responses to trichostatin A. Overall, these findings indicate that the subcellular localization of MBD3 together with its localization on the specific promoters and the trichostatin A-induced transcriptional regulation may be important in the determination of cellular susceptibility to trichostatin A.
Discussion
Cancer cells exhibit genomic instability due to multiple genetic defects, so strategies targeting single genetic abnormalities are therapeutically ineffective. However, accumulating evidence has shown that cancer cells also suffer from epigenetic alterations that can be pivotal to carcinogenesis via inactivation of tumor suppressors and/or activation of oncogenes (1) (2) (3) (4) (5) (6) . Previous studies have identified drugs capable of targeting epigenetic regulation; some of these show cancer selectivity (lower cytotoxicity against normal cells), indicating that they may be promising candidates for anticancer therapeutics (34) (35) (36) (37) (38) (39) (40) (41) . One subset of these drugs, the HDIs, induces histone acetylation, which can lead to reactivation of transcriptionally silenced genes or inactivation of transcriptionally hyperactive genes (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) . Here, we showed that HDIs exhibited cancer-selective cytotoxicity ( Fig. 4D ; data not shown) and cancer-specific transcriptional modulation (Table 1 ; Fig. 1 ).
Microarray analysis was used to identify differentially expressed genes that seem to be related with trichostatin A treatment of cancer cells, including tumor suppressors and oncogene, such as regulators of cell cycle, growth, and apoptosis (Table 1 ; Fig. 1 ). Thus, our data indicate that HDIs fulfill their cancer-selective roles through both transcriptional activation and silencing.
Our mechanistic analysis of cancer-selective growth inhibition by trichostatin A revealed that the growth inhibition effects were associated with reduced proliferation and apoptosis and occurred in a transcription-dependent manner (data not shown; Fig. 2 ). Trichostatin A-induced cancer-selective cell death was associated with up-regulation of p21 WAF1/Cip1 and down-regulation of ErbB2 (Fig. 2) , and overexpression of p21 WAF1/Cip1 or silencing of ErbB2 inhibited cancer cell growth without regard to trichostatin A (Fig. 2) . Therefore, our results indicate that the selective antitumor activities of HDIs seem to require transcriptional modulation of cancer-specific gene expressions, including up-regulation of p21 WAF1/Cip1 and down-regulation of ErbB2. Importantly, chromatin immunoprecipitation analyses of proteins released from or recruited to the p21 WAF1/Cip1 and ErbB2 gene promoters revealed that trichostatin A treatment resulted in dissociation/association of MBD1-MBD3 at the activated/inactivated promoters, respectively (Fig. 3) . Treatment of cancer cells with trichostatin A caused release of MBD3 from the p21 WAF1/Cip1 promoter, whereas treatment of normal cells caused recruitment of MBD3 to this promoter, suggesting a reverse correlation between MBD3 binding and p21 WAF1/Cip1 mRNA expression (Fig. 1) . Consistent with this, we observed another reverse correlation between MBD3 association with ErbB2 promoter (Fig. 3) and reduced ErbB2 mRNA expression (Fig. 1 ) in cancer cells. On the other hand, both trichostatin A-induced up-regulation/down-regulation and protein recruitment differed between two cancer cell lines at the E-cadherin promoter (Fig. 3C) , indicating that trichostatin A responses can differ in terms of MBD recruitment and transcriptional activation not only between cancer and normal cells but also between cancer types. However, our observations of MBD3 association/dissociation in trichostatin A-treated cells seem to indicate that MBD3 dissociates from the up-regulated promoter and associates with the down-regulated promoter following trichostatin A treatment. Here, our findings provide evidence that MBD3 may be another facet of the complex machinery influencing transcriptional status.
Unexpectedly, HDIs could induce histone acetylation at the promoters without regard to transcriptional expression. Repression of ErbB2 and E-cadherin expression in the trichostatin A-treated cancer cells was accompanied by increased histone acetylation (Fig. 3) , suggesting that the open chromatin structure induced by HDAC inhibition may facilitate the access of transcriptional activators and repressors equally well; thus, binding of repressor (e.g., MBD3 and HDACs) to promoter may result in transcriptional repression. Thus, the nature of the complex formed at the promoter can be determined by the global chromatin context and a wide range of factors, such as histone modification profile, DNA methylation pattern, or even growth and differentiation stages.
The striking trichostatin A-induced recruitment of MBD3 to the ErbB2 promoter and its release from the p21 WAF1/Cip1 promoter in cancer cells led us to speculate about the role of MBD3 in HDI-induced differential gene expression and cancerselective death. Previous reports indicated that MBD1 and MBD2 preferentially bind to methylated DNA, whereas MBD3 preferentially binds unmethylated DNA (26) (27) (28) . Notably, HDIs modulate histone acetylation/deacetylation but not DNA methylation. Indeed, we found that silencing of MBD3 abrogated HDI-induced transcriptional reprogramming and growth inhibition in HDItreated cancer cells (Fig. 4A and B) but not in normal cells (Fig. 4C and D) . We further showed that MBD3, but not MBD1 and MBD2, was relocalized within cells in response to HDI treatment, and this localization differed between cancer and normal cells (Fig. 5) . Thus, the relocation of MBD3 to the nucleus may facilitate MBD3 recruitment to the genome and allow MBD3 to function as a regulatory molecule. We additionally noted that MBD1 and MBD2 dissociated/associated differently in HDItreated cancer and normal cells. Collectively, these results indicate that MBD3 likely plays a role in mediating the cancerselective effects of HDI in transcriptional modulation and growth inhibition and that further work is warranted to examine whether silencing of MBD1 and MBD2 affects HDI-induced cancer-selective effects.
HDI-induced cancer-selective cytotoxicity is likely regulated by complex mechanisms. Our data indicate the importance of differential gene expression, protein localization, and histone acetylation/deacetylation. Moreover, HDIs are known to regulate additional proteins, such as a-tubulin and heat shock proteins, which may affect additional biochemical processes and physiologic phenomena. Nevertheless, our data indicate that the MBD proteins may play underlying roles in the nuclear/transcriptional effects of HDIs on cancer cells. Our observation that MBD3 silencing blocks HDI-induced cancer cell-specific gene regulation and selective cytotoxicity provides strong evidence for role of MBD3 in mediating cancer selectivity of HDIs. Thus, we have herein advanced our understanding of HDI-induced cancerselective effects by exploring key molecular transcriptional changes in response to HDI treatment in lung cancer and Role of MBD3 in Cancer-Selective Cytotoxicity by HDIs www.aacrjournals.org normal cells. Our experiments revealed that MBD3 is differentially located in lung cancer and normal cells at both chromatin and cellular levels leading to differential transcription and cancer-selective cytotoxicity. In this way, our work provides new insights into the value of HDIs and their future potential in cancer treatment.
